Effects of Tianxiangdan Granule treatment on atherosclerosis via NF‑κB and p38 MAPK signaling pathways

Sun,Long‑Fei; An,Dong‑Qing; Niyazi,Gu‑Lijiamali; Ma,Wen‑Hui; Xu,Zheng‑Wei; Xie,Yang

doi:10.3892/mmr.2017.8067

Effects of Tianxiangdan Granule treatment on atherosclerosis via NF‑κB and p38 MAPK signaling pathways

Authors:
- Long‑Fei Sun
- Dong‑Qing An
- Gu‑Lijiamali Niyazi
- Wen‑Hui Ma
- Zheng‑Wei Xu
- Yang Xie
View Affiliations

Affiliations: Coronary Care Unit, Affiliated Hospital of Traditional Chinese Medicine, Xinjiang Medical University, Urumqi, Xinjiang 830000, P.R. China, Department of Traditional Chinese Medicine, College of Traditional Chinese Medicine, Xinjiang Medical University, Urumqi, Xinnjiang 830011, P.R. China, Rehabilitation Unit, Affiliated Hospital of Traditional Chinese Medicine, Xinjiang Medical University, Urumqi, Xinjiang 830000, P.R. China
Published online on: November 15, 2017 https://doi.org/10.3892/mmr.2017.8067
Pages: 1642-1650
Copyright: © Sun et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to determine the effects of Tianxiangdan Granule on nuclear factor (NF)-κB p65 and p38 mitogen‑activated protein kinase (MAPK) inflammatory signaling pathways, and explored the possible mechanism underlying the effects of Tianxiangdan Granule on prevention and treatment of atherosclerosis. A total of 48 apolipoprotein E‑/‑ mice (age, 8 weeks) were selected and divided into two groups: The normal control group (n=12) and the modeling group (n=36). In the modeling group, mice were fed a high‑fat diet and were maintained in an artificial climate box, in order to stimulate the climate and eating habit characteristics of Xinjiang. Every morning, ApoE‑/‑ mice in the modeling group were placed in the artificial climate box at 10:00 am and were taken out at 09:00 pm and placed back in the room temperature environment. The temperature of the artificial climate box was set at 6±2˚C, relative humidity was controlled at 25‑32.8% and the light‑dark cycle was 12 h/day. The purpose of this method was to establish the Huizhuo Tanzu type atherosclerosis model. Following successful generation of the model, mice in the modeling group were randomly divided into three groups: Model group (n=10), Tianxiangdan group (n=10) and atorvastatin group (n=10). After 12 weeks, mice were sacrificed and the serum levels of interleukin (IL)‑1β and tumor necrosis factor (TNF)‑α in each group were detected. Furthermore, the expression levels of NF‑κB p65 and p38 MAPK in aortic tissue were detected. The results indicated that the concentrations of IL‑1β and TNF‑α were significantly higher in mice in the model group compared with in the normal control group (P<0.01), whereas the concentrations of IL‑1β and TNF‑α were lower in the Tianxiangdan and atorvastatin groups compared with in the model group (P<0.01). Furthermore, the protein expression levels of phosphorylated (p)‑NF‑κB p65 and p‑p38 MAPK protein were higher in aortic tissues from the model group compared with in the normal control group (P<0.01), p‑NF‑κB p65 and p‑p38 MAPK protein expression was reduced in the atorvastatin and Tianxiangdan groups compared with in the model group. The present study indicated that the mechanism underlying the effects of Tianxiangdan Granule on the prevention and treatment of atherosclerosis may be as follows: Tianxiangdan Granule may decrease the expression of the inflammatory cytokines IL‑1β and TNF‑α, and suppress activation of the NF‑κB p65 and p38 MAPK signaling pathways.

View Figures

View References

1	Lehrke M and Lebherz C: AAV-mediated gene therapy for atherosclerosis. Curr Atheroscler Rep. 16:4342014. View Article : Google Scholar
2	Sidney S, Rosamond WD, Howard VJ and Luepker RV: National Forum for Heart Disease and Stroke Prevention: The ‘heart disease and stroke statistics-2013 update’ and the need for a national cardiovascular surveillance system. Circulation. 127:21–23. 2013. View Article : Google Scholar
3	Chen WW, Gao RL and Liu LS: The Chinese cardiovascular disease report 2014 Profile. Chin Circulat J. 617–622. 2015.
4	Anogeianaki A, Angelucci D, Cianchetti E, D'Alessandro M, Maccauro G, Saggini A, Salini V, Caraffa A, Tete S, Conti F, et al: Atherosclerosis: A classic inflammatory disease. Int J Immunopathol Pharmacol. 24:817–825. 2011. View Article : Google Scholar
5	Charakida M, O'Neil F, Masi S, Papageorgiou N and Tousoulis D: Inflammatory disorders and atherosclerosis: New therapeutic approaches. Curr Pharm Des. 17:4111–4120. 2011. View Article : Google Scholar
6	Hansson GK: Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 352:1685–1695. 2005. View Article : Google Scholar
7	Ross R: Atherosclerosis is an inflammatory disease. Am Heart J. 138:S419–S420. 1999. View Article : Google Scholar
8	An D, Hu J, Zhao M and Zheng J: Effect of Tianxiangdan on serum vascular endothelial growth factor and correlative factors in coronary heart disease. Chin J Integrat Med Cardio/Cerebrovas Dis. 5:662–664. 2007.(In Chinese).
9	An D, Zhou M, Zhang X and Ling C: Effect of Tianxiangdan on thrombosis and myocardial ultramicrostructure in rat model with myocadial ischemia. J Xinjiang Med Uni. 30:434–437. 2007.(In Chinese).
10	Yin J, Zhu J, Liu Q and An Q: The effect of Tianxiangdan granule on T-SOD, GSH-Px, MDA, LD in serum of angina of coronary heart disease patients. Chin J Inform Trad Chin Med. 10:13–15. 2003.(In Chinese).
11	Wang XY, Jiao YJ and An DQ: Effects of different concentrations of Tianxiangdan on blood lipid and VEGF levels in ApoE (−/-) gene knockout mice with atherosclerosis. J Emer Trad Chin Med. 23(400–403): 415S42014.(In Chinese).
12	An DQ: A medicine for treating coronary heart disease and its preparation method. CN200910210063.9. Filed Nov 4, 2009; issued May 11. 2011.
13	Gao Z, Ablimiti A and Wufuer H: Thinking about the establishment of animal model of cold dryness syndrome in Northwest China. Chin J Inf Tradit Chin Med. 17:6–7. 2010.(In Chinese).
14	Niyazi G, An DQ and Li M: Study on Establishing Animal Model of Huizhuo Tanzu Type Atherosclerosis. Chin J Exp Tradit Med Form. 19:265–269. 2013.(In Chinese).
15	Xu SY, Bian RL and Chen X: The Experimental Method of Pharmacology. Third edition. Beijing: People's Med Publishing House; 2013, (In Chinese). View Article : Google Scholar
16	Lucas AR, Korol R and Pepine CJ: Inflammation in atherosclerosis: Some thoughts about acute coronary syndromes. Circulation. 113:e728–e732. 2006. View Article : Google Scholar
17	Li YJ, Yang Q and Zhu XX: TCM anti-inflammation: An effective approach for treating atherosclerosis. Mod Tradit Chin Med Mater Med-World Sci Technol. 9:22–28. 2007.(In Chinese).
18	Daviglus ML, Talavera GA, Avilés-Santa ML, Allison M, Cai J, Criqui MH, Gellman M, Giachello AL, Gouskova N, Kaplan RC, et al: Prevalence of major cardiovascular risk factors and cardiovascular diseases among hispanic/latino individuals of diverse backgrounds in the United States. JAMA. 308:1775–1784. 2012. View Article : Google Scholar :
19	Sen R and Baltimore D: Multiple unclear factors interact with the immunoglobulin enhancer sequences. Cell. 46:705–716. 1986. View Article : Google Scholar
20	Gordon JW, Shaw JA and Kirshenbaum LA: Multiple facets of NF-κB in the heart: To be or not to NF-κB. Circ Res. 108:1122–1132. 2011. View Article : Google Scholar
21	Ghosh S, May MJ and Kopp EB: NF-kappa B and Rel proteins: Evolutionarily conserved mediators of immune responses. Annu Rev Immunol. 16:225–260. 1998. View Article : Google Scholar
22	Misra A, Haudek SB, Knuefermann P, Vallejo JG, Chen ZJ, Michael LH, Sivasubramanian N, Olson EN, Entman ML and Mann DL: Nuclear factor-kappaB protects the adult cardiac myocyte against ischemia-induced apoptosis in a murine model of acute myocardial infarction. Circulation. 108:3075–3078. 2003. View Article : Google Scholar
23	Morita M, Yano S, Yamaguchi T and Sugimoto T: Advanced glycation end products-induced reactive oxygen species generation is partly through NF-kappa B activation in human aortic endothelial cells. J Diabetes Complications. 27:11–15. 2013. View Article : Google Scholar
24	Lawrence T, Gilroy DW, Nash Colwille PR and Willoughby DA: Possible new role for NF-kappa B in the resolution of inflammation. Nat Med. 7:1291–1297. 2001. View Article : Google Scholar
25	Freund C, Schmidt-Ullrich R, Baurand A, Dunger S, Schneider W, Loser P, El-Jamali A, Dietz R, Scheidereit C and Bergmann MW: Requirement of nuclear factor-kappaB in angiotensin II- and isoproterenol-induced cardiac hypertrophy in vivo. Circulation. 111:2319–2325. 2005. View Article : Google Scholar
26	Zelarayan L, Renger A, Noack C, Zafiriou MP, Gehrke C, van der Nagel R, Dietz R, de Windt L and Bergmann MW: NF-kappaB activation is required for adaptive cardiac hypertrophy. Cardiovasc Res. 84:416–424. 2009. View Article : Google Scholar
27	Liuzzo G, Santamaria M, Biasucci LM, Narducci M, Colafrancesco V, Porto A, Brugaletta S, Pinnelli M, Rizzello V, Maseri A and Crea F: Persistent activation of nuclear factor kappa-B signaling pathway in patients with unstable angina and elevated levels of C-reactive protein evidence for a direct proinflammatory effect of azide and lipopolysaccharide-free C-reactive protein on human monocytes via nuclear factor kappa-B activation. J Am Coll Cardiol. 49:185–194. 2007. View Article : Google Scholar
28	Wu XL, Zheng B, Jin LS, Zhang RN, He M, Yang Z and Wen JK: Chinese medicine Tongxinluo reduces atherosclerotic lesion by attenuating oxidative stress and inflammation in microvascular endothelial cells. Int J Clin Exp Pathol. 8:6323–6333. 2015.
29	Kang Q, Liu W, Liu H and Zhou M: Effect of compound chuanxiong capsule on inflammatory reaction and PI3K/Akt/NF-κB signaling pathway in atherosclerosis. Evid Based Complement Alternat Med. 2015:5845962015. View Article : Google Scholar :
30	Latkovslds G, Licis N and Kalnms U: C-reactive protein levels and common polymorphisms of the interleukin-1 gene cluster and interleukin-6 gene in patients with coronary heart disease. Eur J Immunogenet. 31:207–213. 2004. View Article : Google Scholar
31	Zhu T, Zhang L, Ling S, Duan J, Qian F, Li Y and Xu JW: Scropolioside B inhibits IL-1β and cytokines expression through NF-κB and inflammasome NLRP3 pathways. Mediators Inflamm. 2014:8190532014. View Article : Google Scholar :
32	Popa C, Netea MG, van-Riel PL, van der Meer JW and Stalenhoef AF: The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. J Lipid Res. 48:751–762. 2007. View Article : Google Scholar
33	Zhang H, Park Y, Wu J, Chen Xp, Lee S, Yang J, Dellsperger KC and Zhang C: Role of TNF-alpha in vascular dysfunction. Clin Sci (Lond). 116:219–230. 2009. View Article : Google Scholar :
34	Novitskiy G, Ravi R, Potter JJ, Rennie-Tankersley L, Wang L and Mezey E: Effects of acetaldehyde and TNF alpha on the inhibitory kappa B-alpha protein and nuclear factor kappa B activation in hepatic stellate cells. Alcohol Alcohol. 40:96–101. 2005. View Article : Google Scholar
35	Morello S, Ito K, Yamamura S, Lee KY, Jazrawi E, Desouza P, Barnes P, Cicala C and Adcock IM: IL-1beta and TNF-alpha regulation of the adenosine receptor (A2A) expression: Differential requirement for NF-kappa B binding to the proximal promoter. J Immunol. 177:7173–7183. 2006. View Article : Google Scholar
36	Schramek H: MAP kinases: From intracellular signals to physiology and disease. News Physiol Sci. 17:62–67. 2002.
37	Garrington TP and Johnson GL: Organization and regulation of mitogen-activated protein kinase signaling pathways. Curr Opin Cell Biol. 11:211–218. 1999. View Article : Google Scholar
38	Dunn KL, Espino PS, Drobic B, He S and Davie JR: The Ras-MAPK signal transduction pathway, cancer and chromatin remodeling. Biochem Cell Biol. 83:1–14. 2005. View Article : Google Scholar
39	Ju H, Behm DJ, Nerurkar S, Eybye ME, Haimbach RE, Olzinski AR, Douglas SA and Willette RN: p38 MAPK inhibitors ameliorate target organ damage in hypertension: Part1. p38 MAPK-dependent endothelial dysfunction and hypertension. J Pharmacol Exp Ther. 307:932–938. 2003. View Article : Google Scholar
40	Goldstein DM and Gabriel T: Pathway to the clinic: Inhibition of P38 MAP kinase. A review of ten chemotypes selected for development. Curr Top Med Chem. 5:1017–1029. 2005. View Article : Google Scholar
41	He X, Shu J, Xu L, Lu C and Lu A: Inhibitory effect of astragalus polysaccharides on lipopolysaccharide-induced TNF-a and IL-1β production in THP-1 cells. Molecules. 17:3155–3164. 2012. View Article : Google Scholar
42	Yang K, Qiu BY, Yan J, Yang YX, Zhang T, Chen X, Zou YP, Gan HT and Huang XL: Blockade of p38 mitogen-activated protein kinase pathway ameliorates delayed gastric emptying in streptozotocin-induced diabetic rats. Int Immunopharmacol. 23:696–700. 2014. View Article : Google Scholar
43	El Bekay R, Alvarez M, Monteseirín J, Alba G, Chacón P, Vega A, Martin-Nieto J, Jiménez J, Pintado E, Bedoya FJ and Sobrino F: Oxidative stress is a critical mediator of the angiotensin II signal in human neutrophils: Involvement of mitogen-activated protein kinase, calcineurin, and the transcription factor NF-kappaB. Blood. 102:662–671. 2003. View Article : Google Scholar
44	Lindroos PM, Rice AB, Wang YZ and Boner JC: Role of nuclear factor-kappaB and mitogen-activated protein kinase signaling pathways in IL-1beta-mediated induction of alpha-PDGF receptor expression in rat pulmonary myofibroblasts. Immunol. 161:3464–8. 1998.
45	Zhang X, Wu M, Jiang H, Hao J, Zhang Q, Zhu Q, Saren G, Zhang Y, Meng X and Yue X: Angiotensin II upregulates endothelial lipase expression via the NF-kappa B and MAPK signaling pathways. PLoS One. 9:e1076342014. View Article : Google Scholar :
46	An DQ, Zhao MF, Zheng J, et al: Xinjiang obstruction of dirty phlegm syndrome retraces. Xinjiang J Tradit Chin Med. 25:1–2. 2007.(In Chinese).
47	Xiao Y, Wang YC, Li LL, Jin YC, Sironi L and Wang Y and Wang Y: Lactones from Ligusticum chuanxiong Hort. reduces atherosclerotic lesions in apoE-deficient mice via inhibiting over expression of NF-kB-dependent adhesion molecules. Fitoterapia. 95:240–246. 2014. View Article : Google Scholar
48	Liang CJ, Lee CW, Sung HC, Chen YH, Wang SH, Wu PJ, Chiang YC, Tsai JS, Wu CC, Li CY and Chen YL: Magnolol reduced TNF-α-induced vascular cell adhesion molecule-1 expression in endothelial cells via JNK/p38 and NF-κB signaling pathways. Am J Chin Med. 42:619–636. 2014. View Article : Google Scholar
49	Chen Z, Cai Y, Zhang W, Liu X and Liu S: Astragaloside IV inhibits platelet-derived growth factor-BB-stimulated proliferation and migration of vascular smooth muscle cells via the inhibition of p38 MAPK signaling. Exp Ther Med. 8:1253–1258. 2014. View Article : Google Scholar :
50	Shen DZ, Xin SL, Chen C and Liu T: Effect of atorvastatin on expression of TLR4 and NF-κB p65 in atherosclerotic rabbits. Asian Pac J Trop Med. 6:493–496. 2013. View Article : Google Scholar
51	Bao MH, Zhang YW and Zhou HH: Paeonol suppresses oxidized low-density lipoprotein induced endothelial cell apoptosis via activation of LOX-1/p38MAPK/NF-κB pathway. J Ethnopharmacol. 146:543–551. 2013. View Article : Google Scholar
52	Liang CJ, Lee CW, Sung HC, Chen YH, Wang SH, Wu PJ, Chiang YC, Tsai JS, Wu CC, Li CY and Chen YL: Magnolol reduced TNF-α-induced vascular cell adhesion molecule-1 expression in endothelial cells via JNK/p38 and NF-κB signaling pathways. Am J Chin Med. 42:619–637. 2014. View Article : Google Scholar
53	Park Haeng S, Sung YY, Nho Jin K and Kim Kyoung H: Anti-atherosclerotic effects of Polygonum aviculare L. ethanol extract in ApoE knock-out mice fed a Western diet mediated via the MAPK pathway. J Ethnopharmacol. 151:1109–1115. 2014. View Article : Google Scholar
54	Chang YL, Chen CL, Kuo CL, Chen BC and You JS: Glycyrrhetinic acid inhibits ICAM-1 expression via blocking JNK and NF-kappaB pathways in TNF-alpha-activated endothelial cells. Acta Pharmacol Sin. 31:546–553. 2010. View Article : Google Scholar :